RPRX news

Latest 1 stories · newest Aug 5, 2026

RPRX

Royalty Pharma Rises Portfolio Receipts Guidance to $3.4-$3.5B

The company reported strong Q2 2026 results and raised its full-year Portfolio Receipts guidance range. Additionally, it announced capital deployment of $1.1 billion and pipeline updates including FDA and EC approvals for several partnered therapies.

Earnings|Guidance|M&A|Offering Aug 5, 2026 sentiment +0.40 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same RPRX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/RPRX/newsSTART FREE